Anavex Reports Fiscal First Quarter 2015 Financial Results

NEW YORK, NY – February 18, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three months ended December 31, 2014. Financial Highlights:…

Amarantus Announces First Alzheimer’s Biomarker Services Collaboration for LymPro Test® with Anavex Life Sciences Corp.

Investigational Alzheimer’s drug candidate ANAVEX 2-73 and drug combination ANAVEX PLUS pharmacodynamic activity to be evaluated using Amarantus’ LymPro Test® in blood samples from Alzheimer’s disease patients Companies to establish scope of biomarker services (initial patient screening for enrollment and ongoing monitoring of drug activity) for clinical trial following ongoing Phase 2a study for ANAVEX…